A palmitoyl-tailed sequential oligopeptide carrier for engineering immunogenic conjugates

Area of Science:

• Biotechnology
• Immunology
• Materials Science

Background:

• Designing effective vaccine immunogens requires combining B/T cell epitopes and adjuvants on a carrier.
• Current carriers often necessitate additional immunostimulators for potent immune responses.

Purpose of the Study:

• To develop a novel helicoid type sequential oligopeptide carrier (SOC(n)-II) for potential human vaccine applications.
• To evaluate the immunogenicity of a conjugate using the palmitoylated carrier (Palm-SOC(n)-II) linked to a key B cell epitope from the Sm autoantigen.

Main Methods:

• A helicoid oligopeptide carrier, SOC(n)-II, was synthesized and modified with a palmitoyl group for inherent adjuvanticity.
• The Sm autoantigen's B cell epitope (PPGMRPP) was conjugated to the carrier (Palm-SOC(4)-II-Sm(4)).
• Animal immunizations were performed with the conjugate without external adjuvants, and immune responses were analyzed.

Main Results:

• The conjugate Palm-SOC(4)-II-Sm(4) induced high titers of specific antibodies without supplementary adjuvants.
• The immune response was comparable to conventional immunization protocols using Freund's adjuvant.
• Generated antibodies recognized the immunogenic conjugate and Sm mimics but not the carrier alone.

Conclusions:

• The palmitoylated SOC(n)-II carrier is effective in engineering immunogens for enhanced and specific humoral immune responses.
• This carrier shows promise for developing self-adjuvanting vaccine candidates.
• The study contributes to the development of carriers for human vaccine applications.